Interestingly, multiple analyses of cancer surgical specimens and cancers from various cell lines have shown substantially higher TRPV6 expression in prostate, breast, thyroid, colon, and ovarian cancers relative to their noncancerous counterparts [107,108,109,110], which could suggest the participation of TRPV6 in the pathological process [111,112], favoring the hypothesis of its involvement in the selectivity of the inhibitory properties of CAP. Here, TRPV6 is linked to ovarian cancer.